1xbet 후기 Pharmaceutical Co., Ltd.

1xbet 후기 Pharmaceutical Co., Ltd. (1xbet 후기) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for their Digital Medicine, a drug/device combination product, which combines 1xbet 후기's ABILIFY® (aripiprazole), an atypical antipsychotic, with the FDA-cleared Proteus ingestible sensor embedded in a single tablet at point of manufacture. The NDA was submitted as a system that measures medication adherence to aripiprazole to be indicated for the treatment of schizophrenia, as an acute treatment of manic and mixed episodes associated with Bipolar I Disorder (BP1) and as an adjunctive treatment for Major Depressive Disorder (MDD).

FDA has completed its review and has requested additional 1xbet 후기formation, 1xbet 후기clud1xbet 후기g data regard1xbet 후기g the performance of the product under the conditions 1xbet 후기 which it is likely to be used, and further human factors 1xbet 후기vestigations. The goal of human factors test1xbet 후기g is to evaluate use-related risks and confirm that users can use the device safely and effectively.

"While we are disappointed in the FDA's decision not to approve this Digital Medicine at this time, both 1xbet 후기 and Proteus are committed to working with the FDA to address its questions and provide the additional data that has been requested," said Robert McQuade, executive vice president and chief strategy officer, 1xbet 후기 Pharmaceutical Development & Commercialization, Inc. "We believe in the potential of this product to help people with serious mental illness manage their daily medication, which remains a serious unmet need."^*1

1. 1Kane JM, Kishimoto T, Correll CU. Nonadherence to medication 1xbet 후기 patients with psychotic disorders: epidemiology, contribut1xbet 후기g factors and management strategies. World Psychiatry. 2013;12:216-226